not tagged
not tagged
['breast', 'novartis']
quality of life (qol) differences between cdk4/6 inhibitors &amp; their associated adverse event profiles may impact clinical decisions in hr+/her2- #metastaticbreastcancer. learn more about the matching-adjusted indirect analysis presented by at #asco22 [1/2]
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu